Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Mirkina, Irina ^a   Hadzijusufovic, Emir ^a,b   Krepler, Clemens ^a,c   Mikula, Mario ^a,c   Mechtcheriakova, Diana ^a   Strommer, Sabine ^a   Stella, Alexander ^a   Jensen Jarolim, Erika ^a,b   Höller, Christoph ^c   Wacheck, Volker ^a   Pehamberger, Hubert ^a,c   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; AFATINIB; CANERTINIB; CD133 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CD63 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERYTHROPOIETIN RECEPTOR; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR GAMMA; LINSITINIB; MCS 2156119J 15; MIDOSTAURIN; MULTIDRUG RESISTANCE PROTEIN 1; NERVE GROWTH FACTOR RECEPTOR; NILOTINIB; PELITINIB; PROGRAMMED DEATH 1 RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; MALE; MELANOMA; MICE; MICE, INBRED NOD; NEOPLASM TRANSPLANTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, ERYTHROPOIETIN; SKIN NEOPLASMS;

EID: 84900384946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084417     Document Type: Article

References (36)

1. de Vries E, Coebergh JW (2004) Cutaneous malignant melanoma in Europe. Eur J Cancer 40: 2355-2366.
2. Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, et al. (2004) Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer 101: 2067-2078. (Pubitemid 39425384)
3. Pho L, Grossman D, Leachman SA (2006) Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 18: 173-179. (Pubitemid 43740438)
4. MacKie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20 Suppl 6: vi1-7.
5. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351: 998-1012.
6. La Porta CA (2009) Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 9: 391-397.
7. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, et al. (2008) Melanoma-induced brain metastases. Expert Rev Anticancer Ther 8: 743-755.
8. Haluska F, Pemberton T, Ibrahim N, Kalinsky K (2007) The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 34: 546-554. (Pubitemid 350236312)
9. Dhomen N, Marais R (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23: 529-545, ix.
10. Smalley KS, Herlyn M (2009) Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer 124: 1245-1250.
11. Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36: 71-78. (Pubitemid 39424129)
12. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24: 223-236. (Pubitemid 40922796)
13. Bonitsis N, Batistatou A, Karantima S, Charalabopoulos K (2006) The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 28: 187-193. (Pubitemid 44735907)
14. Radford KJ, Thorne RF, Hersey P (1996) CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Commun 222: 13-18. (Pubitemid 26160050)
15. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, et al. (2000) Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10: 421-426.
16. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, et al. (2005) Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166: 823-830. (Pubitemid 40315639)
17. Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, et al. (2009) ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res 19: 156-166.
18. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946. (Pubitemid 46366698)
19. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
20. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
21. Heine M, Nollau P, Masslo C, Nielsen P, Freund B, et al. (2011) Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. PLoS One 6:e28030.
22. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
23. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133-137.
24. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
25. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
26. Mechtcheriakova D, Sobanov Y, Holtappels G, Bajna E, Svoboda M, et al. (2011) Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component. PLoS One 6: e25611.
27. Mirmohammadsadegh A, Marini A, Gustrau A, Delia D, Nambiar S, et al. (2010) Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 130: 201-210.
28. Kumar SM, Yu H, Fong D, Acs G, Xu X (2006) Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 16: 275-283. (Pubitemid 44090171)
29. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, et al. (2012) Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 31: 1649-1660.
30. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, et al. (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14: 6821-6828.
31. Passegue E, Rafii S, Herlyn M (2009) Cancer stem cells are everywhere. Nat Med 15: 23.
32. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12: 767-775.
33. Natarajan N, Telang S, Miller D, Chesney J (2011) Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 71: 1233-1250.
34. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H (2012) Melanoma: new insights and new therapies. J Invest Dermatol 132: 854-863.
35. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12: 349-361.
36. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, et al. (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197.